glp-1 clinical trial Receptor Agonists as Treatments for Type 2 Diabetes The Big Trial of a

requiring multiple injections in a short time

In EMPA-REG OUTCOME, the kidney composite of albuminuria progression, doubling of serum creatinine, end-stage kidney disease (ESKD), or renal death was reduced by 39%, with consistent benefits across multiple subgroups including those with chronic kidney disease (CKD) at baseline [34]

Mounjaro is a once-weekly injection containing tirzepatide, which targets two hormones, GLP-1 and GIP , and it's shown the strongest average weight loss results in clinical trials, at around 22.5% over 72 weeks

Brand and Retailer Takeaways Consumer satisfaction with GLP-1 medications for weight loss is very high and steps are underway by manufacturers to reduce side effects and lower costs, likely leading to a reduction in the current rates of discontinued use